InvestSMART

Antisense Therapeutics Limited (ASX: ANP) - Announcements

Current share price for ANP : $0.058 0.003 (4.92%)+

ASX company news and announcements for Antisense Therapeutics Limited (ANP) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Antisense Therapeutics Limited (ANP) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Antisense Therapeutics Limited (ANP), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Antisense Therapeutics Limited (ANP)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$52 Market Update 14 May 2020 9:40AM $0.046 $0.058 risen by 26.09%
$52 Change in substantial holding from AEF 7 May 2020 12:31PM $0.048 $0.058 risen by 20.83%
$52 Antisense to present at NWR Virtual Health Network 1 May 2020 4:20PM $0.048 $0.058 risen by 20.83%
$52 Change in substantial holding from AEF 27 Apr 2020 5:08PM $0.049 $0.058 risen by 18.37%
$52 Change in substantial holding from AEF 24 Apr 2020 6:15PM $0.049 $0.058 risen by 18.37%
$52 Quarterly Update and Appendix 4C 21 Apr 2020 10:51AM $0.047 $0.058 risen by 23.40%
$52 Change in substantial holding from AEF 1 Apr 2020 6:48PM $0.045 $0.058 risen by 28.89%
$52 Phase II DMD trial database lock and final results on track 18 Mar 2020 9:45AM $0.041 $0.058 risen by 41.46%
$52 ATL1102 Phase II data to be presented at DMD Conference 5 Mar 2020 9:25AM $0.059 $0.058 fallen by 1.69%
$52 Half Yearly Report and Half Year Accounts 28 Feb 2020 3:06PM $0.060 $0.058 fallen by 3.33%
$52 Appointment of US-based Consultant Medical Director 27 Feb 2020 9:12AM $0.061 $0.058 fallen by 4.92%
$52 Results in DMD unlock value creation potential of ATL1102 6 Feb 2020 9:48AM $0.060 $0.058 fallen by 3.33%
$52 Quarterly Update & Appendix 4C 30 Jan 2020 10:49AM $0.070 $0.058 fallen by 17.14%
$52 ANP Presentation for SACHS 3rd Neuroscience Innovation Forum 13 Jan 2020 9:20AM $0.082 $0.058 fallen by 29.27%
$52 ANP to Present at Neuroscience Innovation Forum in the US 10 Jan 2020 10:55AM $0.081 $0.058 fallen by 28.40%
$52 Antisense Therapeutics Limited - Listed Options raise $5.5M 3 Jan 2020 12:39PM $0.087 $0.058 fallen by 33.33%
$52 Appendix 3B and 708A notice 3 Jan 2020 12:35PM $0.087 $0.058 fallen by 33.33%
$52 Change of Director's Interest Notice (RM, MD, GM, GP, WG) 24 Dec 2019 9:10AM $0.087 $0.058 fallen by 33.33%
$52 Appendix 3B 23 Dec 2019 1:25PM $0.089 $0.058 fallen by 34.83%
$52 Change in substantial holding 23 Dec 2019 11:22AM $0.090 $0.058 fallen by 35.56%
$52 Change in substantial holding from AEF 20 Dec 2019 5:06PM $0.093 $0.058 fallen by 37.63%
$52 Change of Director's Interest Notice - WG 20 Dec 2019 9:48AM $0.093 $0.058 fallen by 37.63%
$52 Change of Director's Interest Notice - RM 20 Dec 2019 9:47AM $0.093 $0.058 fallen by 37.63%
$52 Appendix 3B 19 Dec 2019 1:17PM $0.090 $0.058 fallen by 35.56%
$52 Change of Director's Interest Notice (RM) 19 Dec 2019 8:46AM $0.086 $0.058 fallen by 32.56%

226 - 250 of 707 results

Page 10 of 29

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.